Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

Summary

The purpose of the study is to see if using an investigational drug called \[18F\]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a treatment study. The results of this study will not change a patient's clinical treatment plan but it may help physicians and researchers better understand how best to treat patients with breast cancer in the future.

Timeline

Start

2022-03-25

Primary completion

2027-08

Completion

2027-08

Drugs

Indications